Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Rectal Cancer Clinical Trial

Official title:

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04620473
• Other study ID #: MISC-Anlotinib+Capeox
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 1, 2023
• Est. completion date: October 1, 2024

Study information

• Verified date: September 2021
• Source: Shanghai Minimally Invasive Surgery Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects voluntarily join the study and sign an informed consent form, have good compliance and cooperate with follow-up;

2. Male or female patients between the ages of 18-75;

3. Patients diagnosed as rectal adenocarcinoma by histology or cytology;

4. Stage: Locally advanced stage (T3-4N0M0 or T1-4N+M0);

5. Evaluation of middle and low rectal cancer with the lower pole of the tumor less than 12 cm from the anal margin by MRI;

6. Have not received other anti-angiogenic drugs or chemotherapy drugs in the past;

7. ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points;

8. Has sufficient organ and bone marrow function

Exclusion Criteria:

1. Other malignant tumors that have appeared or are currently suffering from within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1 (tumor infiltration basement membrane)];

2. A distant transfer occurs;

3. Those who have multiple factors that affect oral medications (such as inability to swallow, chronic diarrhea, etc.);

4. Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AE V5.0 grade = 2 dyspnea);

5. Patients with any severe and/or uncontrollable disease;

6. Patients with gastrointestinal diseases with bleeding tendency (such as active gastrointestinal ulcers) or patients determined by the researcher to cause gastrointestinal bleeding, perforation or obstruction

7. Patients whose imaging shows that the tumor has invaded the tissues around important blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the follow-up study;

8. Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before grouping;

9. Regardless of the severity, patients with any signs of bleeding or medical history; within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTC AE V5.0 grade = 3, unhealed wounds, ulcers Or fracture

10. Those who have had arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism;

11. People with a history of psychotropic drug abuse and unable to quit or have mental disorders;

12. Participated in other anti-tumor drug clinical trials within four weeks;

13. According to the judgment of the investigator, those with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study;

14. Female patients who are pregnant or breastfeeding;

15. Known hypersensitivity to any study drug.

Related Conditions & MeSH terms

• Anlotinib
• Neoadjuvant Treatment
• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• Anlotinib+Capeox
to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
• Capeox
to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Minimally Invasive Surgery Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate(ORR)	Refers to the proportion of subjects whose tumors have shrunk to a certain amount and maintained for a certain period of time in the FAS concentration, including CR and PR cases	an average of three months
Secondary	Pathological complete response rate	Refers to the pathological examination of primary tumors and lymph node surgical specimens without residual infiltrating tumor cells (ypT0N0)	one month after surgery
Secondary	R0 resection rate	Refers to the surgically removed tissue without residual cancer cells	one month after surgery
Secondary	Local disease recurrence time	Refers to the tumor reappearing at or near the same site as the primary cancer. The starting time is the first day after surgery.	3 years after surgery
Secondary	Overall survive	Refers to the time from the start of randomization to death due to any cause. The starting time is the first day after surgery.	3 years after surgery
Secondary	Disease-free survival rate	It refers to the time from the beginning of randomization to the incurable resection, local recurrence or metastasis, or death from any cause. The starting time is the first day after surgery.	3 years after surgery
Secondary	Postoperative complications	Postoperative complications	one month after surgery